Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Exploratory, single-dose, open-label, pharmacokinetic study to establish uptake, plasma levels safety and tolerability of orally administered AUX-001 on an empty stomach (i.e, fasting) as well as after a meal (i.e. fed) in healthy volunteers.
This is a first-in-human, exploratory, single-dose, open-label pharmacokinetic study to explore the uptake, and systemic distribution of orally administered AUX-001 in healthy volunteers on an empty stomach (i.e, fasting) as well as after a meal (i.e. fed) in male and female healthy volunteers age 18 to 55 to establish pharmacokinetics, safety, tolerability and whether the medication can be given independent of any food effect.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm A: fasting | Experimental | AUX-001 40mg QD |
|
| Arm B: fed | Experimental | AUX-001 40mg QD |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AUX-001 40mg once-daily | Drug | AUX-001 (extended-release nicorandil) 40mg QD (once-daily) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Area under the curve over 24 hours [AUC0-24h)] of nicorandil under fasting conditions | Total nicorandil plasma concentration over 24 hours under fasting conditions | 24 hours |
| Area under the curve over 24 hours [AUC0-24h)] of nicorandil under fed conditions | Total nicorandil plasma concentration over 24 hours under fed conditions | 24 hours |
| Maximum Plasma Concentration [Cmax] of nicorandil under fasting conditions | Peak plasma concentration under fasting conditions in mcg/ml | 24 hours |
| Maximum Plasma Concentration [Cmax] of nicorandil under fed conditions | Peak plasma concentration under fed conditions in mcg/ml | 24 hours |
| 24 hour Area Under the Curve [AUC0-24h] of N-(2-hydroxyethyl) nicotinamide under fasting conditions | 24 hour Total Plasma Concentration of nicorandil's main metabolite under fasting conditions | 24 hours |
| 24h hour Area Under the Curve [AUC0-24h] of N-(2-hydroxyethyl) nicotinamide under fed conditions | Total Plasma Concentration of nicorandil's main metabolite under fed conditions | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment-emergent adverse events [TEAE] under fasting conditions | Occurrence of treatment-emergent adverse events (TEAEs) including vital signs, pulse oximetry, EKG, liver function tests [LFT] under fasting conditions | 24 hours |
| Treatment-emergent adverse events [TEAE] under fed conditions |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marlene Fonseca, MD | Blueclinical, Ltd. | Principal Investigator |
| Uwe P Tigör, MD | Auxilius Pharma | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| BlueClinical | Porto | 4250-449 | Portugal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D060050 | Angina, Stable |
| D005215 | Fasting |
| D007863 | Lecithin Cholesterol Acyltransferase Deficiency |
| ID | Term |
|---|---|
| D000787 | Angina Pectoris |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Single-dose clinical trial with healthy volunteers sequentially using a single dose of AUX-001 under fasting and thereafter under fed conditions
Not provided
Not provided
Not provided
Not provided
Occurrence of treatment-emergent adverse events (TEAEs) including vital signs, pulse oximetry, EKG, liver function tests [LFT] under fed conditions |
| 24 hours |
| D014652 |
| Vascular Diseases |
| D002637 | Chest Pain |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D005247 | Feeding Behavior |
| D001519 | Behavior |
| D052456 | Hypoalphalipoproteinemias |
| D007009 | Hypolipoproteinemias |
| D008052 | Lipid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |